Trilogy Capital’s Novo Nordisk NVO Stock Holding History

Trilogy Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-98	Closed	-$2K	–	426
2018 Q3	$2K	Hold	98	–	–	﹤0.01%	510
2018 Q2	$2K	Hold	98	–	–	﹤0.01%	470
2018 Q1	$2K	Buy	+98	New	+$2.57K	﹤0.01%	398

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Trilogy Capital's NVO Position: Q4 2018 in Review

Trilogy Capital sold out of Novo Nordisk (NVO) in Q4 2018, closing a stake of 98 shares — an estimated $2K sold.

Trilogy Capital first reported a position in NVO in Q1 2018 and held it in 3 quarters. The position peaked at $2K in Q3 2018. 550 funds tracked by Wall St. Rank hold NVO as of Q4 2018.

Trilogy Capital reported no remaining Novo Nordisk position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 98 Novo Nordisk shares in Q4 2018, an estimated $2K.
Trilogy Capital first reported a position in Novo Nordisk in Q1 2018 and held it in 3 quarters.
Trilogy Capital's Novo Nordisk position peaked at $2K in Q3 2018.
550 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.